Cart (0 Items)
Your cart is currently empty.
View ProductsTogether we succeed
Case Reports
We are proud to partner with 9 000+ customers from biotech innovators, pharmaceutical leaders, and academic pioneers worldwide.
-
Antibody Drug Conjugate
Struggling to conjugate your antibody to a cytotoxic payload while preserving integrity and controlling DAR? Discover how ProteoGenix developed a site-specific Vc-MMAE ADC with a DAR of 3.8 and 92.2% monomeric purity—delivering 6 mg of characterized ADC ready for preclinical studies.
-
CAR-T cell development
130 Validated Antibody Candidates in 3 Weeks Powering CAR-T Therapy for Breast Cancer
Need a large, high-confidence antibody panel to fuel your CAR-T program? Discover how ProteoGenix screened 480 phage-display binders and delivered 130 fully validated, unique sequences in just 3 weeks—all confirmed specific by re-validation ELISA.
-
CAR-T cell development
Rapid Discovery of Selective Anti-pHLA Antibodies for CAR-T Cell Therapy in Melanoma
Struggling to find antibodies that hit your cancer target without cross-reacting with similar molecules? Discover how ProteoGenix screened over 2×10¹¹ clones across three proprietary libraries to identify 4 highly selective anti-pHLA candidates—one of which went on to validate a CAR-T therapy in preclinical assays.
-
VHH antibody production
Need to rapidly build a diverse panel of VHH candidates against a challenging immune checkpoint? Discover how ProteoGenix delivered 14 unique PD-1-targeting VHH sequences in just 3 weeks—exceeding the guaranteed minimum of 3, with 5 confirmed blockers.
-
Bispecific antibody development
Engineering Seven Bispecific Antibody Formats Yielding Nanomolar Leads Against Prostate Cancer
Struggling to find the right bispecific format without sacrificing affinity? Discover how ProteoGenix engineered seven bispecific antibody formats against two prostate cancer targets—identifying three top candidates with nanomolar affinity down to 3.20×10⁻¹⁰ M.
-
Custom hybridoma generation
Powering dynamic metabolic control research with highly specific antibodies generated by hybridoma
Struggling to detect engineered protein tags without false positives? Discover how ProteoGenix developed a highly selective antibody for DMC’s DAS+4 tag with 14.3-fold specificity—enabling precise metabolic control in fermentation.
-
AI-driven Affinity Maturation Services
Accelerating neurology diagnostic development with AI-driven Antibody Affinity Maturation
A pharmaceutical company had identified a promising mouse antibody against a human antigen for neurodegenerative disease diagnostics, but its sensitivity was too low for reliable detection. ProteoGenix leveraged AI-driven paratope–epitope mapping and targeted mutation design to select and test 20 variants, yielding lead candidates with up to a 20-fold affinity improvement—without compromising developability or backbone structural stability.
-
AI-driven Antibody Humanization Service
Successful antibody humanization for cervical cancer therapy with improved binding
ProteoGenix supported a small French biotech in humanizing a mouse-derived antibody for cervical cancer in 3 weeks, using an AI-guided, stepwise mutation design strategy across 22 humanized variants. Structural checks plus ELISA validation confirmed reduced immunogenicity risk (>80% homology to the human sequence) while improving binding, with several variants reaching up to a 2.6-fold increase—leading to three prioritized candidates.
-
Custom VHH Production
Accelerating VHH Discovery for Translational Development
ProteoGenix helped Heidelberg University rapidly progress from antigen to validated VHHs leads through phage display expertise, rigorous screening, and dedicated scientific support.
-
Epitope Mapping Services
By combining AI predictions with experimental validation, ProteoGenix delivered reliable antibody–antigen insights, reducing risks and timelines and guiding therapeutic, diagnostic, and IP strategies.
-
Custom Antibody Services
TCR-Like Antibody Development For Cancer Immunotherapy
ProteoGenix rapidly generated high-affinity TCR-like antibodies against a difficult peptide–HLA target, using rabbit immunization and a custom phage display library. This approach delivered three validated candidates that advanced the client’s CAR-T immunotherapy program.
-
Custom Diagnostic & Research Antibody
Custom Antibody Production and SPR Expertise from ProteoGenix Advance Blood–Brain Barrier Research
ProteoGenix’s antibodies and data helped the team confirm Unc5B’s role in blood–brain barrier integrity. The study showed how Netrin-1–Unc5B signaling supports stability and that antibody blockade can safely open the barrier, bridging research with neuroscience applications.
-
Transient antibody production services
Delivering Preclinical-Grade Antibodies with XtenCHO® Race Mid-Scale Production
The scale-up confirmed that the candidate remains promising for further development. The client obtained the large quantity they required under strict purity conditions, allowing them to confidently continue their program.
-
Transient antibody production services
Fast-Tracking Variant Selection with XtenCHO® Race Small-Scale High-Throughput Production
Early yield evaluation with XtenCHO® Race enabled a rapid first selection of candidates. This allowed the client to save time and money while keeping the quality and consistency needed to confidently advance their therapeutic program with their new variants selection.
